fibrinolyt potenti gliclazid type II diabet patient studi effect gliclazid tissue-typ plasminogen activ t-pa fibrinolysi type diabet patient residu beta-cel function type II diabet patient tolbutamid type diabet patient period month type II diabet patient tolbutamid type diabet patient month treatment gliclazid signific increas plasma concentr total t-pa antigen stabl discontinu drug plasma concentr plasminogen activ inhibitor pai studi next possibl gliclazid t-pa-rel fibrinolysi subset type II diabet detect concentr t-pa treatment tolbutamid concentr activ t-pa month chang treatment activ t-pa patient undetect level month gliclazid plasma concentr total t-pa antigen group diabet patient pai unchang chang t-pa-rel fibrinolysi type type II diabet chang metabol state blood glucos cholesterol triglycerid gliclazid potenti extrametabol non-insulin-medi effect t-pa-rel fibrinolysi diabet patient 